Antibiotic use, pulmonary exacerbations and hospitalisations by treatment group
| Azithromycin (N=61) | Placebo (N=54) | Difference (95% CI) | |
| Oral antibiotic use Participants with ≥1 event, n (%) | 7 (11.5) | 11 (20.4) | −8.9% (−22.7 to 4.6) |
| Intravenous antibiotic use Participants with ≥1 event, n (%) | 3 (4.9) | 2 (3.7) | 1.2% (−8.2 to 10.2) |
| Inhaled antibiotic use (other than tobramycin) Participants with ≥1 event, n (%) | 1 (1.6) | 2 (3.7) | −2.1% (−11.0 to 5.5) |
| Pulmonary exacerbation Participants with ≥1 event, n (%) | 9 (14.8) | 8 (14.8) | −0.1% (−13.7 to 13.0) |
| Hospitalisation Participants with ≥1 event, n (%) | 3 (4.9) | 3 (5.6) | −0.6% (−10.7 to 8.7) |